Cargando…

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment

The ALK tyrosine kinase receptor is oncogenically activated in neuroblastoma. Whereas numerous ALK fusion genes have been reported in different malignancies, in neuroblastoma ALK is mainly activated through point mutations. Three hotspot residues (F1174, F1245, and R1275) account for 85% of mutant A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Javanmardi, Niloufar, Fransson, Susanne, Djos, Anna, Sjöberg, Rose-Marie, Nilsson, Staffan, Truvé, Katarina, Kogner, Per, Martinsson, Tommy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379392/ https://www.ncbi.nlm.nih.gov/pubmed/30778092 http://dx.doi.org/10.1038/s41598-018-37240-z

Ejemplares similares

Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation
por: Djos, Anna, et al.
Publicado: (2022)

Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene
por: Djos, Anna, et al.
Publicado: (2013)

Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma
por: Carén, Helena, et al.
Publicado: (2011)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas
por: Fransson, Susanne, et al.
Publicado: (2013)

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma
por: Djos, Anna, et al.
Publicado: (2012)

Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes
por: Thorell, Kaisa, et al.
Publicado: (2009)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma
por: Rasmuson, Agnes, et al.
Publicado: (2012)

Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance
por: Fransson, Susanne, et al.
Publicado: (2020)

Identification of recurrent 3q13.31 chromosomal rearrangement indicates LSAMP as a tumor suppressor gene in neuroblastoma
por: Martinez-Monleon, Angela, et al.
Publicado: (2023)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours
por: Carén, H, et al.
Publicado: (2007)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma
por: Keane, Simon, et al.
Publicado: (2021)

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
por: Martinez-Monleon, Angela, et al.
Publicado: (2022)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
por: Guan, J., et al.
Publicado: (2016)

A genome-wide scan to locate regions associated with familial vesicoureteral reflux
por: Bartik, Zsuzsa, et al.
Publicado: (2022)

Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors
por: Kryh, Hanna, et al.
Publicado: (2011)

A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation
por: Carén, Helena, et al.
Publicado: (2005)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene
por: Carén, Helena, et al.
Publicado: (2008)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors
por: Olsson, Maja, et al.
Publicado: (2016)

Platform Comparison for Evaluation of ALK Protein Immunohistochemical Expression, Genomic Copy Number and Hotspot Mutation Status in Neuroblastomas
por: Yan, Benedict, et al.
Publicado: (2014)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

5′ ALK Amplification in Neuroblastoma: A Case Report
por: Akhavanfard, Sara, et al.
Publicado: (2021)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT
por: Debruyne, D N, et al.
Publicado: (2016)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas
por: Miyazaki, Makoto, et al.
Publicado: (2018)

Activating mutations in ALK provide a therapeutic target in neuroblastoma
por: George, Rani E., et al.
Publicado: (2008)

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_256oc8g8cmo1kplci5e8cflosa